Inclusive clinical trials: Why we really shouldn't still be talking about this in 2024 (but have to!)

In 2022, the US’s National Academy of Sciences, Engineering & Medicine (NASEM) released a damning report into underrepresentation in clinical trials. "While progress has been made with representation of white women in clinical trials and clinical research, there has been little progress in the last three decades to increase participation of racial and ethnic minority population groups." Whilst we celebrate diversity in Europe, from race to gender, sexuality to age, participants in clinical trials remain overwhelmingly white and male. However, until interest and investment to improve diversity and representativeness in trials comes to the forefront, the goals of diversification remain poorly articulated and understood. We all know how important diversity is, but how exactly can we make clinical trials attractive to all?